Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
AMS vs NNOX vs GEHC vs NVCR vs SYK
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Healthcare Information Services
Medical - Instruments & Supplies
Medical - Devices
AMS vs NNOX vs GEHC vs NVCR vs SYK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Devices | Medical - Healthcare Information Services | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $13M | $115M | $27.90B | $1.92B | $112.69B |
| Revenue (TTM) | $29M | $12M | $19.95B | $674M | $25.12B |
| Net Income (TTM) | $-2M | $-56M | $1.50B | $-173M | $3.25B |
| Gross Margin | 25.0% | -98.8% | 42.5% | 75.2% | 63.5% |
| Operating Margin | -12.3% | -469.7% | 12.5% | -27.2% | 22.4% |
| Forward P/E | 6.1x | — | 12.4x | — | 19.6x |
| Total Debt | $23M | $7M | $10.00B | $290M | $14.86B |
| Cash & Equiv. | $11M | $39M | $4.51B | $103M | $4.01B |
AMS vs NNOX vs GEHC vs NVCR vs SYK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Dec 22 | May 26 | Return |
|---|---|---|---|
| American Shared Hos… (AMS) | 100 | 68.6 | -31.4% |
| Nano-X Imaging Ltd. (NNOX) | 100 | 23.8 | -76.2% |
| GE HealthCare Techn… (GEHC) | 100 | 105.1 | +5.1% |
| NovoCure Limited (NVCR) | 100 | 22.9 | -77.1% |
| Stryker Corporation (SYK) | 100 | 120.4 | +20.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AMS vs NNOX vs GEHC vs NVCR vs SYK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AMS is the #2 pick in this set and the best alternative if growth exposure and valuation efficiency is your priority.
- Rev growth 32.9%, EPS growth 245.9%, 3Y rev CAGR 17.1%
- PEG 0.93 vs GEHC's 19.78
- 32.9% revenue growth vs GEHC's 4.8%
- Lower P/E (6.1x vs 19.6x), PEG 0.93 vs 1.32
NNOX lags the leaders in this set but could rank higher in a more targeted comparison.
Among these 5 stocks, GEHC doesn't own a clear edge in any measured category.
NVCR ranks third and is worth considering specifically for momentum.
- +1.1% vs NNOX's -64.4%
SYK carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 34 yrs, beta 0.55, yield 1.1%
- 187.1% 10Y total return vs GEHC's 2.9%
- Lower volatility, beta 0.55, Low D/E 66.3%, current ratio 1.89x
- Beta 0.55, yield 1.1%, current ratio 1.89x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 32.9% revenue growth vs GEHC's 4.8% | |
| Value | Lower P/E (6.1x vs 19.6x), PEG 0.93 vs 1.32 | |
| Quality / Margins | 12.9% margin vs NNOX's -452.8% | |
| Stability / Safety | Beta 0.55 vs NVCR's 2.20, lower leverage | |
| Dividends | 1.1% yield, 34-year raise streak, vs GEHC's 0.2%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +1.1% vs NNOX's -64.4% | |
| Efficiency (ROA) | 6.9% ROA vs NNOX's -31.6%, ROIC 11.4% vs -27.9% |
AMS vs NNOX vs GEHC vs NVCR vs SYK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
AMS vs NNOX vs GEHC vs NVCR vs SYK — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
SYK leads in 4 of 6 categories
AMS leads 1 • NNOX leads 0 • GEHC leads 0 • NVCR leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
SYK leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SYK is the larger business by revenue, generating $25.1B annually — 2041.6x NNOX's $12M. SYK is the more profitable business, keeping 12.9% of every revenue dollar as net income compared to NNOX's -4.5%. On growth, NNOX holds the edge at +13.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $29M | $12M | $20.0B | $674M | $25.1B |
| EBITDAEarnings before interest/tax | $2M | -$46M | $3.3B | -$165M | $6.3B |
| Net IncomeAfter-tax profit | -$2M | -$56M | $1.5B | -$173M | $3.2B |
| Free Cash FlowCash after capex | -$10M | -$47M | $1.5B | -$48M | $4.3B |
| Gross MarginGross profit ÷ Revenue | +25.0% | -98.8% | +42.5% | +75.2% | +63.5% |
| Operating MarginEBIT ÷ Revenue | -12.3% | -4.7% | +12.5% | -27.2% | +22.4% |
| Net MarginNet income ÷ Revenue | -7.6% | -4.5% | +7.5% | -25.7% | +12.9% |
| FCF MarginFCF ÷ Revenue | -34.7% | -3.8% | +7.6% | -7.1% | +17.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.5% | +13.7% | +7.4% | +12.3% | +11.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -56.7% | +8.7% | -30.9% | -100.0% | +56.0% |
Valuation Metrics
AMS leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 6.1x trailing earnings, AMS trades at a 83% valuation discount to SYK's 35.0x P/E. Adjusting for growth (PEG ratio), AMS offers better value at 0.93x vs GEHC's 19.78x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $13M | $115M | $27.9B | $1.9B | $112.7B |
| Enterprise ValueMkt cap + debt − cash | $25M | $83M | $33.4B | $2.1B | $123.5B |
| Trailing P/EPrice ÷ TTM EPS | 6.09x | -1.93x | 13.48x | -13.80x | 35.03x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 12.40x | — | 19.62x |
| PEG RatioP/E ÷ EPS growth rate | 0.93x | — | 19.78x | — | 2.36x |
| EV / EBITDAEnterprise value multiple | 7.51x | — | 10.00x | — | 20.31x |
| Price / SalesMarket cap ÷ Revenue | 0.46x | 10.20x | 1.35x | 2.92x | 4.49x |
| Price / BookPrice ÷ Book value/share | 0.45x | 0.55x | 2.66x | 5.51x | 5.02x |
| Price / FCFMarket cap ÷ FCF | — | — | 18.53x | — | 26.31x |
Profitability & Efficiency
SYK leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
SYK delivers a 15.0% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-51 for NVCR. NNOX carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to GEHC's 0.94x. On the Piotroski fundamental quality scale (0–9), SYK scores 6/9 vs GEHC's 4/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -7.9% | -35.5% | +14.4% | -50.8% | +15.0% |
| ROA (TTM)Return on assets | -3.8% | -31.6% | +4.1% | -16.5% | +6.9% |
| ROICReturn on invested capital | -5.8% | -27.9% | +13.3% | -16.4% | +11.4% |
| ROCEReturn on capital employed | -6.4% | -28.4% | +10.8% | -28.9% | +13.0% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 | 4 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.77x | 0.04x | 0.94x | 0.85x | 0.66x |
| Net DebtTotal debt minus cash | $12M | -$32M | $5.5B | $187M | $10.8B |
| Cash & Equiv.Liquid assets | $11M | $39M | $4.5B | $103M | $4.0B |
| Total DebtShort + long-term debt | $23M | $7M | $10.0B | $290M | $14.9B |
| Interest CoverageEBIT ÷ Interest expense | -1.35x | -379.29x | 5.35x | -96.80x | 6.72x |
Total Returns (Dividends Reinvested)
SYK leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SYK five years ago would be worth $12,152 today (with dividends reinvested), compared to $605 for NNOX. Over the past 12 months, NVCR leads with a +1.1% total return vs NNOX's -64.4%. The 3-year compound annual growth rate (CAGR) favors SYK at 1.8% vs NNOX's -52.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -4.3% | -37.8% | -25.9% | +28.3% | -15.2% |
| 1-Year ReturnPast 12 months | -27.4% | -64.4% | -10.7% | +1.1% | -22.5% |
| 3-Year ReturnCumulative with dividends | -28.0% | -89.2% | -22.2% | -75.7% | +5.5% |
| 5-Year ReturnCumulative with dividends | -41.1% | -93.9% | +2.9% | -91.3% | +21.5% |
| 10-Year ReturnCumulative with dividends | -4.7% | -96.1% | +2.9% | +30.3% | +187.1% |
| CAGR (3Y)Annualised 3-year return | -10.4% | -52.4% | -8.0% | -37.6% | +1.8% |
Risk & Volatility
Evenly matched — AMS and NVCR each lead in 1 of 2 comparable metrics.
Risk & Volatility
AMS is the less volatile stock with a -0.02 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs NNOX's 30.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.02x | 1.86x | 1.37x | 2.20x | 0.55x |
| 52-Week HighHighest price in past year | $3.11 | $5.86 | $89.77 | $20.06 | $404.87 |
| 52-Week LowLowest price in past year | $1.25 | $1.66 | $58.75 | $9.82 | $289.91 |
| % of 52W HighCurrent price vs 52-week peak | +64.6% | +30.0% | +68.3% | +83.9% | +72.7% |
| RSI (14)Momentum oscillator 0–100 | 63.8 | 38.5 | 32.1 | 69.8 | 24.3 |
| Avg Volume (50D)Average daily shares traded | 138K | 1.4M | 4.3M | 1.5M | 2.1M |
Analyst Outlook
SYK leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: NNOX as "Buy", GEHC as "Buy", NVCR as "Buy", SYK as "Buy". Consensus price targets imply 922.7% upside for NNOX (target: $18) vs 36.9% for GEHC (target: $84). For income investors, SYK offers the higher dividend yield at 1.14% vs GEHC's 0.23%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $18.00 | $84.00 | $33.50 | $403.69 |
| # AnalystsCovering analysts | — | 5 | 18 | 15 | 50 |
| Dividend YieldAnnual dividend ÷ price | — | — | +0.2% | — | +1.1% |
| Dividend StreakConsecutive years of raises | 0 | — | 3 | — | 34 |
| Dividend / ShareAnnual DPS | — | — | $0.14 | — | $3.36 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.7% | 0.0% | 0.0% |
SYK leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). AMS leads in 1 (Valuation Metrics). 1 tied.
AMS vs NNOX vs GEHC vs NVCR vs SYK: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is AMS or NNOX or GEHC or NVCR or SYK a better buy right now?
For growth investors, American Shared Hospital Services (AMS) is the stronger pick with 32.
9% revenue growth year-over-year, versus 4. 8% for GE HealthCare Technologies Inc. (GEHC). American Shared Hospital Services (AMS) offers the better valuation at 6. 1x trailing P/E, making it the more compelling value choice. Analysts rate Nano-X Imaging Ltd. (NNOX) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AMS or NNOX or GEHC or NVCR or SYK?
On trailing P/E, American Shared Hospital Services (AMS) is the cheapest at 6.
1x versus Stryker Corporation at 35. 0x. On forward P/E, GE HealthCare Technologies Inc. is actually cheaper at 12. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 32x versus GE HealthCare Technologies Inc. 's 19. 78x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — AMS or NNOX or GEHC or NVCR or SYK?
Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +21.
5%, compared to -93. 9% for Nano-X Imaging Ltd. (NNOX). Over 10 years, the gap is even starker: SYK returned +187. 1% versus NNOX's -96. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AMS or NNOX or GEHC or NVCR or SYK?
By beta (market sensitivity over 5 years), American Shared Hospital Services (AMS) is the lower-risk stock at -0.
02β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately -14141% more volatile than AMS relative to the S&P 500. On balance sheet safety, Nano-X Imaging Ltd. (NNOX) carries a lower debt/equity ratio of 4% versus 94% for GE HealthCare Technologies Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — AMS or NNOX or GEHC or NVCR or SYK?
By revenue growth (latest reported year), American Shared Hospital Services (AMS) is pulling ahead at 32.
9% versus 4. 8% for GE HealthCare Technologies Inc. (GEHC). On earnings-per-share growth, the picture is similar: American Shared Hospital Services grew EPS 245. 9% year-over-year, compared to 4. 8% for GE HealthCare Technologies Inc.. Over a 3-year CAGR, NNOX leads at 105. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AMS or NNOX or GEHC or NVCR or SYK?
Stryker Corporation (SYK) is the more profitable company, earning 12.
9% net margin versus -474. 3% for Nano-X Imaging Ltd. — meaning it keeps 12. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus -502. 9% for NNOX. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is AMS or NNOX or GEHC or NVCR or SYK more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 32x versus GE HealthCare Technologies Inc. 's 19. 78x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, GE HealthCare Technologies Inc. (GEHC) trades at 12. 4x forward P/E versus 19. 6x for Stryker Corporation — 7. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NNOX: 922. 7% to $18. 00.
08Which pays a better dividend — AMS or NNOX or GEHC or NVCR or SYK?
In this comparison, SYK (1.
1% yield), GEHC (0. 2% yield) pay a dividend. AMS, NNOX, NVCR do not pay a meaningful dividend and should not be held primarily for income.
09Is AMS or NNOX or GEHC or NVCR or SYK better for a retirement portfolio?
For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
55), 1. 1% yield, +187. 1% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +187. 1%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between AMS and NNOX and GEHC and NVCR and SYK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AMS is a small-cap high-growth stock; NNOX is a small-cap quality compounder stock; GEHC is a mid-cap deep-value stock; NVCR is a small-cap quality compounder stock; SYK is a mid-cap quality compounder stock. SYK pays a dividend while AMS, NNOX, GEHC, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.